Brookline Capital Markets Reiterates Buy Rating. $12 Price Target on CTI BioPharma (CTIC), Notes Recent NCCN Announcement "Support Our Outlook"
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
